BACKGROUND

Over the past several years, value assessment frameworks (VAFs) have been applied to a number of key clinical issues. However, the adoption and utilization of these tools varies widely among payers. The primary goal of these VAFs is to provide a standard method for generating evidence-based decision makers and other stakeholders in determining which therapies to consider for coverage in a given treatment area. Despite the increasing breadth of awareness of VAFs, recent literature has shown a wider range of introduction, interest, and consideration in novel cancer treatments among payers in their formal decision-making.

KEYWORDS: ICER, VAFs, CAR-T, P&T, Therapy.